Results 201 to 205 of about 25,067 (205)

Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells

Radiotherapy and Oncology, 2015
Caroline V M Verhagen, Annalisa L E Carli, Mark J O'Connor   +2 more
exaly  

Olaparib

Reactions Weekly, 2020
openaire   +2 more sources

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

New England Journal of Medicine, 2019
Isabelle Ray-Coquard, Sandro Pignata, Keiichi Fujiwara   +2 more
exaly  

Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial

European Journal of Cancer, 2019
Mark E Robson, Kathryn J Ruddy, Seock-Ah Im   +2 more
exaly  

Olaparib

2011
openaire   +1 more source